Investment
CRU-GLOBAL leverages both its own capital and strategic collaborations with investment firms, venture capital, and private equity partners to accelerate early-phase development for innovative BioTech and MedTech companies.
Our current key investment partners include CR-Ventures (Boston) and PMK-Ventures (Singapore). We are also in the process of expanding our clinical development accelerator program, with a European and an additional Singaporean fund expected to join soon. Furthermore, we are actively engaging with university funds and other stakeholders who recognize the value of our de-risking, accelerator model.
- Companies or programs entering Phase I or II clinical trials.
- Pharmaceutical drugs, diagnostic tools, medical technologies.
- Very broad spectrum of clinical indications.
- Europe, North America, Southeast Asia.
Investment scope:
Advancing Healthcare Through Innovation
By providing financial support, industry expertise, and strategic guidance, we aim to be the catalyst that drives our portfolio companies toward successful exits, transforming promising research into real-world impact.
Through our support and collaboration, we offer more than just funding, expertise, and services—we become a key stakeholder in the development process. By actively minimizing technical and professional risks, which can account for up to 60% in clinical development (and even more in neurology), we accelerate progress, secure necessary funding more efficiently, and ensure high-quality clinical execution faster than traditional service providers.
We work closely with our portfolio companies, fully committed from the preclinical stage through to exit—typically anticipated following Phase II completion via an M&A transaction or IPO.